CannaPharmaRx Inc
OTC:CPMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Z
|
Zhuhai Port Co Ltd
SZSE:000507
|
CN |
|
T
|
Telecom Argentina SA
F:TEO
|
AR |
|
Verianos Se
XETRA:VROS
|
DE |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (11.3), the stock would be worth $-0.01 (431% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.4 | $0 |
0%
|
| Industry Average | 11.3 | $-0.01 |
-431%
|
| Country Average | 14.5 | $-0.02 |
-522%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
CannaPharmaRx Inc
OTC:CPMD
|
2.6m USD | -3.4 | -0.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 30 | 41.6 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 21.2 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.8B GBP | 22.8 | 29.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 15.9 | 19.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 11.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.4 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 10.3 | 20.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 8.9 | 17 |
Market Distribution
| Min | 0 |
| 30th Percentile | 10.6 |
| Median | 14.5 |
| 70th Percentile | 20.6 |
| Max | 3 794.4 |
Other Multiples
CannaPharmaRx Inc
Glance View
CannaPharmaRx, Inc. engages in the research and manufacture of cannabinoid-based pharmaceuticals. The company is headquartered in Calgary, Alberta and currently employs 4 full-time employees. The principal activity of the Company is to negotiate, acquire and develop various cannabis cultivation projects throughout Canada. The firm's activities is centered around projects, such as the Great Northern Project, and the acquisition of Ramon Road Production Campus LLC. The firm is focused on producing wholesale cannabis and hemp for the medical market.
